Ticker: STTK

Shattuck Labs, Inc. (NASDAQ: STTK) - Quick take What's happening inside: management has discontinued SL-172154, reallocated spending toward SL-325 (lead DR3 antagonist), plans to start Phase 1 enrollment in Q3 2025, reduced operating expense and cash burn, and executed a Private Placement (Aug 4,...

Shattuck Labs, Inc. (NASDAQ: STTK) Shattuck Labs, Inc. is a biotechnology firm dedicated to developing therapies for inflammatory and immune-mediated diseases. The company's income statement for Q1 2025 shows a mixed financial picture. Key Financial Highlights: Collaboration Revenue: Decreased f...